Chemomab Therapeutics CMMB Stock
Chemomab Therapeutics Price Chart
Chemomab Therapeutics CMMB Financial and Trading Overview
| Chemomab Therapeutics stock price | 0.77 USD |
| Previous Close | 1.7 USD |
| Open | 1.7 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 900 |
| Day's Range | 1.54 - 1.7 USD |
| 52 Week Range | 1.38 - 5.35 USD |
| Volume | 17.3K USD |
| Avg. Volume | 24.29K USD |
| Market Cap | 18.78M USD |
| Beta (5Y Monthly) | -0.230684 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.06 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25 USD |
CMMB Valuation Measures
| Enterprise Value | -13744320 USD |
| Trailing P/E | N/A |
| Forward P/E | -21.250002 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6719368 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.427 |
Trading Information
Chemomab Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.230684 |
| 52-Week Change | -48.79% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.35 USD |
| 52 Week Low | 1.38 USD |
| 50-Day Moving Average | 1.62 USD |
| 200-Day Moving Average | 2.05 USD |
CMMB Share Statistics
| Avg. Volume (3 month) | 24.29K USD |
| Avg. Daily Volume (10-Days) | 15.99K USD |
| Shares Outstanding | 11.05M |
| Float | 5.68M |
| Short Ratio | 14.25 |
| % Held by Insiders | 21.44% |
| % Held by Institutions | 33.57% |
| Shares Short | 326.47K |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 2.94% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:16 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.021% |
| Return on Equity (ttm) | -73.47% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -32201000 USD |
| Net Income Avi to Common (ttm) | -31295000 USD |
| Diluted EPS (ttm) | -2.73 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 32.71M USD |
| Total Cash Per Share (mrq) | 2.96 USD |
| Total Debt (mrq) | 177K USD |
| Total Debt/Equity (mrq) | 0.63 USD |
| Current Ratio (mrq) | 4.827 |
| Book Value Per Share (mrq) | 2.53 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -23845000 USD |
| Levered Free Cash Flow (ttm) | -12993750 USD |
Profile of Chemomab Therapeutics
| Country | United States |
| State | N/A |
| City | Tel Aviv |
| Address | Building 7 |
| ZIP | 6158002 |
| Phone | 972 77 331 0156 |
| Website | https://www.chemomab.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Q&A For Chemomab Therapeutics Stock
What is a current CMMB stock price?
Chemomab Therapeutics CMMB stock price today per share is 0.77 USD.
How to purchase Chemomab Therapeutics stock?
You can buy CMMB shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chemomab Therapeutics?
The stock symbol or ticker of Chemomab Therapeutics is CMMB.
Which industry does the Chemomab Therapeutics company belong to?
The Chemomab Therapeutics industry is Biotechnology.
How many shares does Chemomab Therapeutics have in circulation?
The max supply of Chemomab Therapeutics shares is 14.2M.
What is Chemomab Therapeutics Price to Earnings Ratio (PE Ratio)?
Chemomab Therapeutics PE Ratio is now.
What was Chemomab Therapeutics earnings per share over the trailing 12 months (TTM)?
Chemomab Therapeutics EPS is -2.06 USD over the trailing 12 months.
Which sector does the Chemomab Therapeutics company belong to?
The Chemomab Therapeutics sector is Healthcare.
Chemomab Therapeutics CMMB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}